Despite improvements in pharmacological and non-pharmacological treatments, mortality in heart failure patients remains high, particularly among elderly, male, and African-American patients.
This review highlights that despite advances in heart failure therapies, mortality remains unacceptably high, especially in specific demographic groups and those with reduced ejection fraction.
Heart failure (HF) is a clinical syndrome, which is becoming a major public health problem in recent decades, due to its increasing prevalence, especially in the developed countries, mostly due to prolonged lifespan of the general population as well as the increased of HF patients. The HF treatment, particularly, new pharmacological and non-pharmacological agents, has markedly improved clinical outcomes of patients with HF including increased life expectancy and improved quality of life. However, despite the facts that mortality in HF patients has decreased, it still remains unacceptably high. This review of summarizes the evidence to date about the mortality of HF patients. Despite the impressive achievements in the pharmacological and non-pharmacological treatment of HF patients which has undeniably improved the survival of these patients, the mortality still remains high particularly among elderly, male and African-American patients. Patients with HF and reduced ejection fraction have higher mortality rates, most commonly due to cardiovascular causes, compared with patients HF and preserved ejection fraction.
Bytyçi et al. (Tue,) conducted a review in Heart failure. Despite improvements in pharmacological and non-pharmacological treatments, mortality in heart failure patients remains high, particularly among elderly, male, and African-American patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: